Trump Threatens 50% Tariff on Canadian Aircraft Amid Escalating U.S.-Canada Trade Dispute 
China Factory Activity Slips in January as Weak Demand Weighs on Growth Outlook 
Dollar Struggles as Policy Uncertainty Weighs on Markets Despite Official Support 
Canada’s Trade Deficit Jumps in November as Exports Slide and Firms Diversify Away From U.S. 
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms 
Indonesia Stocks Face Fragile Sentiment After MSCI Warning and Market Rout 
Bank of Canada Holds Interest Rate at 2.25% Amid Trade and Global Uncertainty 
Starmer’s China Visit Signals New Era in UK–China Economic Relations 
Copper Prices Hit Record Highs as Metals Rally Gains Momentum on Geopolitical Tensions 
U.S. and El Salvador Sign Landmark Critical Minerals Agreement to Boost Investment and Trade 
U.S. Dollar Slides for Second Week as Tariff Threats and Iran Tensions Shake Markets 
Asian Currencies Hold Firm as Dollar Rebounds on Fed Chair Nomination Hopes 
Asian Stocks Waver as Trump Signals Fed Pick, Shutdown Deal and Tech Earnings Stir Markets 
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets 
Gold Prices Pull Back After Record Highs as January Rally Remains Strong 
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns 
Asia Stocks Pause as Tech Earnings, Fed Signals, and Dollar Weakness Drive Markets 
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
